Arcellx, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Arcellx, Inc. (ACLX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ACLX insiders buying or selling?
In the last 12 months, Arcellx, Inc. insiders reported 0 open-market purchases ($0) and 10 sales ($15.1M) — net selling of $15.1M. Since February 2022, Trabud has recorded 102 Form 4 filings for ACLX: 6 buys ($91.3M) and 96 sells ($226.5M).
Source: SEC EDGAR Form 4
Key Statistics (February 2022 – Feb 28, 2026)
Total Form 4 filings
102
SEC EDGAR
Insider filers
14
Insider buys (6)
$91.3M
Insider sells (96)
$226.5M
Insider sentiment
Net sellingNet insider flow of $135.2M in net selling since February 2022, and $15.1M in net selling over the last 12 months.
Recent ACLX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 28, 2026 | Elghandour Rami | President, CEO and Chairman of the Board | Sale | 89.9K | $113.92 | $10.2M | SEC ↗ |
| Feb 26, 2026 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sale | 11.2K | $113.82 | $1.3M | SEC ↗ |
| Feb 19, 2026 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sale | 8.4K | $68.29 | $572.6K | SEC ↗ |
| Feb 18, 2026 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sale | 11.3K | $69.51 | $784.8K | SEC ↗ |
| Jan 21, 2026 | David Charles Lubner | Director | Sale | 6.0K | $75.00 | $450.0K | SEC ↗ |
| Jan 15, 2026 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 5.9K | $68.51 | $403.0K | SEC ↗ |
| Jan 14, 2026 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 7.4K | $65.51 | $487.2K | SEC ↗ |
| Jan 13, 2026 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 6.1K | $64.15 | $393.3K | SEC ↗ |
| Nov 18, 2025 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 340 | $90.00 | $30.6K | SEC ↗ |
| Oct 15, 2025 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sale | 5.4K | $91.04 | $488.3K | SEC ↗ |
| Oct 6, 2025 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sale | 5.9K | $86.04 | $511.6K | SEC ↗ |
| Oct 1, 2025 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 21.0K | $81.28 | $1.7M | SEC ↗ |
| Sep 29, 2025 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 73 | $80.16 | $5.9K | SEC ↗ |
| Sep 26, 2025 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 12.4K | $80.12 | $993.2K | SEC ↗ |
| Sep 19, 2025 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 3.6K | $80.01 | $291.5K | SEC ↗ |
| Jun 11, 2025 | Kavita Patel | Director | Sale | 1.5K | $67.36 | $101.0K | SEC ↗ |
| May 29, 2025 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sale | 12.2K | $64.14 | $784.8K | SEC ↗ |
| May 20, 2025 | Kavita Patel | Director | Sale | 1.5K | $58.43 | $87.6K | SEC ↗ |
| Apr 29, 2025 | Kavita Patel | Director | Sale | 1.5K | $64.20 | $96.3K | SEC ↗ |
| Apr 8, 2025 | Kavita Patel | Director | Sale | 1.5K | $57.50 | $86.3K | SEC ↗ |
| Mar 18, 2025 | Kavita Patel | Director | Sale | 1.5K | $71.64 | $107.5K | SEC ↗ |
| Feb 27, 2025 | Elghandour Rami | President, CEO and Chairman of the Board | Sale | 38.3K | $62.02 | $2.4M | SEC ↗ |
| Feb 26, 2025 | Kavita Patel | Director | Sale | 1.5K | $63.16 | $94.7K | SEC ↗ |
| Feb 25, 2025 | Christopher Heery | CHIEF MEDICAL OFFICER | Sale | 10.2K | $63.79 | $647.8K | SEC ↗ |
| Feb 5, 2025 | Kavita Patel | Director | Sale | 1.5K | $64.57 | $96.9K | SEC ↗ |
Showing the 25 most recent of 102 Form 4 filings for Arcellx, Inc..
Most active ACLX insiders
- Christopher Heery38 filings
- Kavita Patel19 filings
- Michelle Gilson17 filings
- Elghandour Rami10 filings
- Jill Carroll5 filings
Ask anything about ACLX insider activity
Use Trabud's AI agent to query Arcellx, Inc.'s Form 4 history in plain English — "Show me ACLX CEO purchases this year" or compare it against any other ticker.
Open the AI agentACLX insider trading FAQ
Are Arcellx, Inc. insiders buying or selling?
In the last 12 months, Arcellx, Inc. insiders reported 0 open-market purchases ($0) and 10 sales ($15.1M) — net selling of $15.1M. Since February 2022, Trabud has recorded 102 Form 4 filings for ACLX: 6 buys ($91.3M) and 96 sells ($226.5M). Over the full record that is net selling of $135.2M.
How many insiders trade ACLX stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Arcellx, Inc.. The most recent filing was accepted on Feb 28, 2026.
Where does Trabud get ACLX insider trading data?
All ACLX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.